Theraflu Grip

Quick links to important sections

Theraflu Grip

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Theraflu Grip

Quick Facts

Property Description
Active Ingredients Acetaminophen + (Decongestant/Antitussive/Expectorant)
Form Powder for Oral Solution, Caplets, Oral Liquid Syrups
Pharmacological Class Analgesic, Antipyretic, Upper Respiratory Combination
Common Use Temporary Symptomatic Relief of Cold and Flu
Origin Synthetic Pharmaceutical Compound

The Identity and Classification of Theraflu Grip

Theraflu Grip is classified as a Nonprescription Over-the-Counter (OTC) Combination Product, falling under the category of an Upper Respiratory Agent, specifically formulated for the temporary, symptomatic relief of discomforts associated with the common cold and influenza. It is a synthetically derived medicinal entity, typically administered via the oral route. The product is clinically recognized for providing relief across multiple symptoms, a key feature that differentiates it from single-agent cold remedies.

This classification as a Combination Product signifies that it incorporates multiple active pharmaceutical ingredients (APIs) within a single preparation to concurrently address several manifestations of illness, allowing the patient to address the various symptoms simultaneously.


Core Composition: The Role of Acetaminophen and Multi-Active Ingredients

The therapeutic core of Theraflu Grip is Acetaminophen (Paracetamol), which acts as the foundational Analgesic and Antipyretic ingredient, serving to relieve pain and reduce fever. This core compound is always co-formulated with at least one additional agent, defining the product as a combination therapy. The product is indicated for use as an agent for multiple symptoms, providing relief from fever, pain, and congestion.

Secondary agents may include Phenylephrine HCl (decongestant), Dextromethorphan HBr (cough suppressant), or Guaifenesin (expectorant), ensuring the product is capable of delivering broad-spectrum relief. This formulation is often marketed with distinct daytime and nighttime variants, with the latter typically containing an added sedating agent, like an antihistamine, to aid sleep. The product is available across various Dosage Forms, including Powder for Oral Solution, Caplets, and Oral Liquid Syrups.


General Therapeutic Purpose: What Theraflu Grip Aims to Achieve

The general purpose of Theraflu Grip is to mitigate the physical discomfort and alleviate the general burden of illness associated with cold and flu symptoms through integrated action. The formulation is designed to offer temporary relief from systemic and localized symptoms, such as minor aches, headache, fever, and nasal blockage, often facilitating continued daily function when dealing with a typical cold or mild flu. Combinations containing Acetaminophen and a decongestant are intended for the management of fever and nasal symptoms. The entire formulation is geared toward delivering temporary symptomatic relief that contributes significantly to the user's comfort and well-being while the body combats the underlying viral infection.

Regulatory References

  1. FDA DailyMed Labeling for Theraflu
  2. FDA DailyMed Labeling
  3. NIH MedlinePlus on Combination Cold Medicines

What side effects are possible with Theraflu Grip?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints for Theraflu Grip, based strictly on government regulatory labeling. The product is an acetaminophen-based combination medicine, and its safety profile reflects risks associated with its active ingredients.


Documented Adverse Reactions

Side effects are categorized by frequency and the body system affected, as formalized in regulatory documents:

Classification Examples of Reactions
Common / Expected Drowsiness, dizziness, mild headache, insomnia, nervousness, dry mouth/nose/throat, upset stomach, nausea, weakness.
Less Common / Rare Severe skin reactions (blisters, rash), severe allergic reactions, blood disorders, palpitations, confusion, liver dysfunction.

Critical Safety Warnings

Regulatory labels highlight the potential for serious adverse reactions:

  • Severe Liver Damage: Risk of overdose-related hepatotoxicity due to the acetaminophen component. This risk is increased with co-administration of alcohol or other acetaminophen-containing drugs.
  • Severe Hypersensitivity: Rare, but potentially fatal, reactions including severe skin conditions (e.g., SJS, TEN) and anaphylactic shock.
  • Cardiovascular Effects: High blood pressure (hypertension) or fast/irregular heartbeat, linked to the decongestant component.

Population-Specific Constraints

The official safety information includes specific usage constraints for certain groups:

  • Children: The product is not for use in children under 12 years of age.
  • Older Adults: Increased sensitivity to effects like dizziness, confusion, and urinary difficulty may occur.
  • Pre-existing Conditions: Specific caution or contraindication applies to individuals with liver disease, heart disease, high blood pressure, diabetes, and thyroid disease, as stated in the label.

Usage Restrictions (Label-Mandated)

The product must not be used with any other medication containing Acetaminophen. It is also contraindicated for use while taking or within two weeks of stopping a Monoamine Oxidase Inhibitor (MAOI).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents mandate that immediate emergency medical care is required for any suspected overdose of Theraflu Grip, even if no symptoms are apparent. Users must contact emergency services or a Poison Control Center immediately due to the risk of delayed, severe consequences, primarily from the acetaminophen component.

Overdose manifestations are complex, resulting from the combination of active ingredients. Early signs may include nausea, vomiting, diaphoresis, and general malaise.


Documented Severe Outcomes

The most serious documented manifestation is potentially fatal hepatic necrosis (liver damage) and renal tubular necrosis. Severe outcomes can also involve the Central Nervous System (CNS), presenting as confusion, convulsions, or coma, and cardiac arrhythmias due to the secondary agents. Overdosage may also lead to Serotonin Syndrome if the antitussive component is present.


Official Overdose Management

Management is symptomatic and supportive. The specific antidote, N-acetylcysteine (NAC), is documented for acetaminophen toxicity, underscoring the time-critical nature of treatment. Hospital monitoring is generally required to track the progression of potential toxicity, particularly in patients with pre-existing hepatic impairment or chronic alcohol use.

Therapeutic Uses of Theraflu Grip

Theraflu Grip: Managing Acute Symptomatic Discomfort


This medicine is commonly used across conditions presenting with acute episodes of cold or flu. It provides supportive relief for symptoms related to physical discomfort, such as fever, minor aches, sore throat, cough, and runny nose. The product is intended for easing symptoms that create noticeable physiological strain.

Focus on Symptom Clusters and Stability

Theraflu Grip is applied across domains where additional symptomatic support is needed. It is relevant when symptoms intensify and supportive relief is needed, as it assists with managing symptom clusters that may become intense or disruptive. This temporary symptomatic assistance is used in areas where short-term symptom management is appropriate, supporting the patient during difficult, acute episodes.

The medicine supports general well-being during symptomatic phases when symptoms interfere with daily functioning. The medicine is commonly applied when symptoms are linked to physical discomfort and physiological strain.

Quick Fact: Used for managing symptom clusters associated with acute episodes.

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Theraflu Grip?

The population eligibility for Theraflu Grip is strictly defined by regulatory documents, focusing on age and pre-existing medical conditions, due to its multi-active composition (Acetaminophen plus cold/flu actives).


Eligibility and Exclusion Rules

Classification Rule Summary Population Restriction
Standard Eligibility Permitted for use in Adults and Adolescents 12 years of age and older under standard labeled conditions. General adult population and adolescents 12+
Absolute Contraindication The medicine is prohibited for patients with severe hepatic impairment, severe hypertension, or severe coronary artery disease. Individuals with severe uncontrolled diseases
Concurrent Medication Ban Use is strictly prohibited if the individual is currently taking or has taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days. Patients on MAOI therapy
Age Restriction The product is not recommended for use in children under 12 years of age. Pediatric groups under 12 years
Physiological Restriction Use is generally not recommended for pregnant or lactating (breastfeeding) women. Pregnant or lactating individuals
Conditional Use Use requires caution in older adults (65+), and in patients with controlled diabetes mellitus or mild-to-moderate renal/hepatic insufficiency. Older adults; patients with specific chronic conditions

What should I know about interactions with other medicines?

The interaction profile for Theraflu Grip is defined by regulatory mandates concerning its combination of active components, typically Acetaminophen, a Decongestant, and an Antitussive. This profile identifies specific restrictions for co-administration and substances that modify drug exposure or increase risk, as documented in government drug labels.

Absolute Co-Administration Prohibitions

Use is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of severe reactions, and a mandatory 14-day washout period is required after stopping the MAOI drug. Co-administration is also prohibited with any other medicinal product containing Acetaminophen to prevent the risk of severe liver damage from exceeding the maximum daily dose.


Pharmacodynamic and Metabolic Interactions

Combining the product with Alcohol, sedatives, or tranquilizers is officially documented to result in pharmacodynamic reinforcement, increasing the risk of marked drowsiness and central nervous system depression. Substances that induce hepatic enzymes, such as certain anticonvulsants (e.g., Phenytoin), can increase the risk of severe liver damage due to altered Acetaminophen metabolism. Co-administration with the anticoagulant Warfarin is documented to increase the effect of blood thinning. Furthermore, Potent CYP2D6 Inhibitors can lead to increased exposure of the antitussive component, resulting in exaggerated effects. Cholestyramine is listed as a substance that may reduce the absorption of Acetaminophen, thereby lowering its exposure.


Specific Interaction Constraints

Certain formulations containing Phenylalanine (from aspartame) carry a specific restriction for individuals with Phenylketonuria (PKU).

Mechanism of Action

Theraflu Grip is a multi-component formulation containing acetaminophen, phenylephrine, and may include an antihistamine such as diphenhydramine, whose collective actions modulate cellular processes across the central and peripheral nervous systems and vascular smooth muscle.

Acetaminophen's primary central effect involves its metabolite N-acylphenolamine (AM404), which acts as an agonist at central Transient Receptor Potential Vanilloid 1 (TRPV1) and Cannabinoid 1 (CB1) receptors, particularly in the brain and spinal dorsal horn. This interaction results in the modulation of nociceptive signaling pathways. Acetaminophen also interferes with the peroxidase activity of cyclooxygenase (COX) enzymes, preferentially COX-2, within the central nervous system, lessening prostaglandin synthesis at the hypothalamic thermoregulatory center.

Phenylephrine functions as a direct-acting selective agonist of alpha1-adrenergic receptors located on vascular smooth muscle, notably within the mucosal lining of the upper respiratory tract. alpha1-receptor activation stimulates the Gq protein signaling cascade, leading to the generation of inositol trisphosphate ( IP3) and diacylglycerol ( DAG). IP3 promotes the release of intracellular calcium from the sarcoplasmic reticulum. The resulting increase in intracellular Ca^2+ concentration induces the contraction of vascular smooth muscle cells, culminating in systemic vasoconstriction.

Diphenhydramine, when present, acts as a competitive antagonist at histamine H1 receptors in peripheral tissues and the central nervous system. This H1-receptor blockade prevents histamine from initiating downstream signaling cascades. Furthermore, it exhibits potent antagonist activity at central and peripheral muscarinic acetylcholine receptors ( mAChR), which contributes to its additional downstream cellular effects.

Dosage and Administration Information

How to Use Theraflu Grip

Administration of this multi-ingredient, over-the-counter product follows specific patterns regarding dosage, frequency, and duration. The medicine is designated for oral administration across all available forms, including caplets, liquid syrups, and powders for oral solution.


Official Dosing and Administration Parameters

Feature Instruction
Route of Administration Oral only.
Standard Single Dose One packet of powder, two caplets, or 30 mL of liquid syrup.
Dosing Interval Repeat dose every six hours as needed.
Daily Maximum Dose Do not exceed three total doses in 24 hours for maximum strength formulations.

Usage Restrictions and Preparation

The medicine is administered intermittently on an as-needed basis for symptomatic relief, not on a mandatory schedule. A key restriction is the 4,000 mg maximum daily limit for Acetaminophen from all sources, which involves tracking any concurrent use of other products containing this ingredient.

For the powder forms, the dose is prepared by dissolving the entire contents of one packet into 8 ounces of hot water; the liquid is then consumed while hot. The product is for use in adults and children 12 years of age and over. Use is confined to short-term self-care, generally not exceeding three consecutive days for fever or seven days for pain before medical consultation is advised.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Theraflu Grip

The research for cold and flu combination medicines like Theraflu Grip is based on short-term, randomized controlled trials (RCTs) and systematic reviews exploring temporary symptom patterns. These studies typically compare the combination ingredients against a placebo, focusing on patient-reported outcomes like Total Symptom Scores (TSS) and changes related to physical discomfort over short time intervals.

Studies Addressing Fever and Minor Aches

The analgesic component (Acetaminophen) was studied for pain and fever across a large volume of research. The evidence for this single-active ingredient comes from numerous systematic reviews, with trials that measured reductions in pain intensity and body temperature. Pharmacokinetic studies research examined the absorption profile of different dosage forms, but these results apply only to the populations studied, typically healthy adults.

Research Landscape for Congestion and Cough Components

Research has explored the effects of decongestant and antitussive components. For the cough component, studies examined objective cough frequency and patient scores. The findings were mixed across various systematic reviews, with overall certainty remains low for some antitussive ingredients due to evidence quality varies. Similarly, for decongestants, findings were mixed for some oral ingredients across specific physiological outcomes, and data for certain groups remain insufficient.

Evidence Available for Special Populations and Research Gaps

Clinical trials primarily focus on healthy adults and adolescents. There is limited information for individuals outside these core demographics, particularly very young children. Study follow-up durations were limited, typically lasting only a few hours to three days, meaning long-term effects are not fully established regarding use over extended periods. Uncertainty is also driven by the heterogeneity in the specific combination formulas studied.

Key Studies & References

  1. NIH DailyMed Drug Label (for a typical Acetaminophen, Decongestant, Antitussive Combination)

Frequently Asked Questions (FAQ)

Common questions about Theraflu Grip (FAQ)

Q: Can I use Theraflu Grip if I'm pregnant or breastfeeding?

Regulatory documents state that Theraflu Grip is generally not recommended for use if you are pregnant or breastfeeding. The official product information advises seeking consultation with a healthcare provider before using the product during these times. This is based on standard regulatory caution regarding combination medications.


Q: Does Theraflu Grip cause drowsiness or affect my ability to drive?

According to the official product information, Theraflu Grip may cause side effects like drowsiness or dizziness in some individuals. Due to this potential, the official labeling advises against driving or operating complex machinery until you know how the medicine affects you.


Q: How long does it take for Theraflu Grip to start working?

The product's regulatory data suggests that the active ingredients may begin to relieve symptoms soon after administration. Individual responses and the exact onset of action can vary. There is no guaranteed timeframe for all users to feel relief.


Q: Is Theraflu Grip safe for children?

Official information states that Theraflu Grip is not intended for use in children under a specific age, and the product is formulated for adults and adolescents. Official labeling states that if treatment is needed for younger children, consultation with a healthcare provider is necessary to determine appropriate alternatives.


Q: What is the maximum number of days I should take Theraflu Grip?

Regulatory documents advise that treatment with Theraflu Grip should typically be limited to a short period to avoid masking a more serious underlying condition. If symptoms persist or worsen after a limited number of days of use, the regulatory guidance indicates that a healthcare professional should be consulted.

How should Theraflu Grip be stored and disposed of?

How to Store and Dispose of Theraflu Grip?

This medication must be stored according to the official product labeling to maintain its stability and effectiveness.

Storage and Handling Requirement Official Guidance
Temperature Store at controlled room temperature, typically 20°C to 25°C (68°F to 77°F).
Protection Keep the product protected from heat and moisture.
Child Safety Always store the medication out of the reach of children.
In-Use Stability Once the powder is dissolved in hot water, the solution should be consumed within 10 to 15 minutes.
Disposal Do not flush unused medicine down a sink or toilet. Unused or expired medication should be disposed of by mixing it with an undesirable substance (such as kitty litter or used coffee grounds) and placing the mixture in a sealed container before throwing it into the household trash. Utilizing a drug take-back program is also recommended when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Theraflu Grip found in:

A-Z Index: